These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29187427)

  • 1. The Role of the Androgen Receptor Signaling in Breast Malignancies.
    Christopoulos PF; Vlachogiannis NI; Vogkou CT; Koutsilieris M
    Anticancer Res; 2017 Dec; 37(12):6533-6540. PubMed ID: 29187427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor signaling pathways as a target for breast cancer treatment.
    Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
    Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
    Kono M; Fujii T; Lim B; Karuturi MS; Tripathy D; Ueno NT
    JAMA Oncol; 2017 Sep; 3(9):1266-1273. PubMed ID: 28301631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review.
    Choupani E; Mahmoudi Gomari M; Zanganeh S; Nasseri S; Haji-Allahverdipoor K; Rostami N; Hernandez Y; Najafi S; Saraygord-Afshari N; Hosseini A
    Pharmacol Rev; 2023 Mar; 75(2):309-327. PubMed ID: 36781219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the androgen receptor in triple-negative breast cancer.
    Shah PD; Gucalp A; Traina TA
    Womens Health (Lond); 2013 Jul; 9(4):351-60. PubMed ID: 23826776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights.
    Anestis A; Zoi I; Papavassiliou AG; Karamouzis MV
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31952272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the androgen receptor in triple-negative breast cancer.
    Gucalp A; Traina TA
    Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
    Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
    Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer.
    You CP; Leung MH; Tsang WC; Khoo US; Tsoi H
    Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceritinib is a novel triple negative breast cancer therapeutic agent.
    Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
    Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research Progress in Androgen Receptor and Triple Negative Breast Cancer].
    Jia MY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Apr; 45(2):303-310. PubMed ID: 37157080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
    Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.
    Christenson JL; Trepel JB; Ali HY; Lee S; Eisner JR; Baskin-Bey ES; Elias AD; Richer JK
    Horm Cancer; 2018 Apr; 9(2):82-94. PubMed ID: 29340907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor.
    Mafuvadze B; Liang Y; Hyder SM
    Oncol Rep; 2014 Oct; 32(4):1727-33. PubMed ID: 25051231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines.
    Crespo B; Illera JC; Silvan G; Lopez-Plaza P; Herrera de la Muela M; de la Puente Yagüe M; Diaz Del Arco C; Illera MJ; Caceres S
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Androgen Receptor: Is It a Promising Target?
    Gucalp A; Traina TA
    Ann Surg Oncol; 2017 Oct; 24(10):2876-2880. PubMed ID: 28766215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
    Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
    Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.